Product
Hyaluronidase
Name
HYALURONIDASE
INN Name
HYALURONIDASE
FDA Approved
Yes
6 clinical trials
1 organization
8 indications
1 document
Indication
MicrostomiaIndication
SclerodermaIndication
Muscle SpasticityIndication
Diffuse Large B-cell LymphomaIndication
Drug SafetyIndication
PainIndication
PostoperativeIndication
Graves' DiseaseClinical trial
Hyaluronidase Via Laser-Assisted Drug Delivery for the Treatment of Scleroderma-induced MicrostomiaStatus: Recruiting, Estimated PCD: 2024-05-01
Clinical trial
Peripheral Modulation of Muscle Stiffness and SpasticityStatus: Recruiting, Estimated PCD: 2024-11-16
Clinical trial
A Phase II Trial Evaluating the Efficacy of Polatuzumab Vedotin With Rituximab, Gemcitabine, Dexamethasone, and Cisplatin (PV-RGDP) Chemotherapy for Relapsed or Refractory Diffuse Large B-cell LymphomaStatus: Recruiting, Estimated PCD: 2028-08-01
Clinical trial
Pilot Study of Appropriate Dosing for Reducing and Removing Hyaluronic Acid Filler With Hyaluronidase: A Randomized Control Clinical TrialStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
Effect of Adding Two Different Doses of Hyaluronidase to Bupivacaine in Ultrasound-Guided Transversus Abdominis Plane (TAP) Block for Post-cesarean Section Analgesia; A Randomized Controlled Double Blinded Study.Status: Recruiting, Estimated PCD: 2023-11-10
Clinical trial
Anti-VEGF Therapy for Acute Thyroid Eye Disease (AcTED Study)Status: Recruiting, Estimated PCD: 2025-09-30
Document
DailyMed Label: HYALURONIDASEOrganization
HF Acquisition Co LLC, DBA HealthFirst